Building ‘Smart’ Cell-Based Therapies
A Northwestern synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.
Engineering cell-based, biological devices that monitor and modify human physiology is a promising frontier in clinical synthetic biology. However, no existing technology enabled bioengineers to build such devices that sense a patient’s physiological state and respond in a customized fashion.
“The project addressed a key gap in the synthetic biology toolbox,” says Joshua Leonard, assistant professor of chemical and biological engineering in Northwestern’s McCormick School of Engineering and Applied Science. “There was no way to engineer cells in a manner that allowed them to sense key pieces of information about their environment, which could indicate whether the engineered cell is in healthy tissue or sitting next to a tumor.”
Funded by the National Academies Keck Futures Initiative and the Defense Advanced Research Projects Agency, the research is available to read online in the journal ACS Synthetic Biology.
Leonard’s team worked for nearly four years to close this gap. The end result is a protein biosensor that sits on the surface of a cell and can be programmed to sense specific external factors. For example, the engineered cell could detect big, soluble protein molecules that indicate that it’s next to a tumor. When the biosensor detects such a factor, it sends a signal into the engineered cell’s nucleus to activate a gene expression program, such as the production of tumor-killing proteins or chemicals. Since this toxic program would be activated only near tumor cells, such an approach could minimize side effects as well as improve therapeutic benefits.
Called a Modular Extracellular Sensor Architecture (MESA), the biosensor platform is completely self-contained so that several different biosensors can be present in a single cell without interfering with one another, allowing bioengineers to build increasingly sophisticated functional programs. The platform is also highly modular, enabling the biosensors to be customized to recognize factors of relevance to various patients’ needs.
“By linking the output of these biosensors to genetic programs, one can build in a certain logical command, such as ‘turn the output gene on when you sense this factor but not that factor,’” Leonard explains. “In that way, you could program a cell-based therapy to specify which cells it should kill.”
Leonard says doctors could potentially collect immune cells from a patient’s body, engineer the cells using MESA, and put them back into the patient. From there, the cells would do the work of detecting cancer or the disease they are designed to identify.
The Latest on: Smart Cell-Based Therapies
[google_news title=”” keyword=”Smart Cell-Based Therapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Smart Cell-Based Therapies
- New technique improves T cell-based immunotherapies for solid tumorson May 1, 2024 at 12:30 pm
Several BiTE therapies are already FDA-approved, but they all target blood cancers (such as blinatumomab, which targets B-cell leukemia). However, clinical trials against solid tumors, which make up ...
- RNUGF ReNeuron Group plcon April 28, 2024 at 10:00 am
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating ...
- Cutting-edge RM6 Million Laboratory Opens at UMMC to Advance Cancer Treatmenton April 23, 2024 at 11:27 pm
Cancer patients can approach UMMC for enquiries on Auxi Therapeutics GMP CAR-T & CGT Laboratory. Blood cancer patients may contact Consultant Clinical Haematologist Prof Dr Bee Ping Chong, and ...
- Anticancer Therapies – Webinars and Online Eventson April 19, 2024 at 8:19 am
Returning for a second year, this online event will provide researchers with a unique opportunity to hear about the advances taking place within cancer research. We will bring together a broad ...
- BioRestorative gains as FDA clears amendment to study on cell therapy candidateon April 16, 2024 at 7:52 am
BioRestorative Therapies (NASDAQ:BRTX ... already established 2024 enrolment completion target. BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little ...
- BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendmenton April 16, 2024 at 12:45 am
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S ...
- Opinion: The revolutionary sickle cell therapieson March 20, 2024 at 5:00 pm
(CNN) — In December, the US Food and Drug Administration (FDA) approved the first two cell-based gene therapies for treating sickle cell disease (SCD) in people ages 12 and older: Casgevy and ...
- Cell Therapies, Vaccines May Work Better If T Cells Have More NAD(H)on March 14, 2024 at 5:00 pm
“With more work, we also believe that this information could potentially be used to improve vaccine strategies and the response and durability of cell-based therapies used to treat cancer and ...
- Legend Biotech Corp. Sponsored ADRon January 15, 2024 at 7:25 pm
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other ...
via Bing News